Baader Bank Aktiengesellschaft Purchases New Holdings in United Therapeutics Corporation $UTHR

Baader Bank Aktiengesellschaft purchased a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) during the fourth quarter, Holdings Channel reports. The firm purchased 2,580 shares of the biotechnology company’s stock, valued at approximately $1,256,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Torren Management LLC bought a new stake in United Therapeutics during the fourth quarter worth about $26,000. Activest Wealth Management increased its holdings in United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 56 shares during the period. WealthCollab LLC raised its position in shares of United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 38 shares in the last quarter. Rakuten Securities Inc. lifted its holdings in shares of United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 46 shares during the period. Finally, Wilmington Savings Fund Society FSB lifted its holdings in shares of United Therapeutics by 125.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after acquiring an additional 49 shares during the period. Institutional investors own 94.08% of the company’s stock.

Insider Activity

In other United Therapeutics news, CEO Martine A. Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction that occurred on Wednesday, May 13th. The stock was sold at an average price of $578.65, for a total value of $5,497,175.00. Following the completion of the sale, the chief executive officer directly owned 40,513 shares in the company, valued at approximately $23,442,847.45. The trade was a 19.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Nilda Mesa sold 258 shares of the business’s stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $581.93, for a total value of $150,137.94. Following the completion of the transaction, the director directly owned 5,028 shares in the company, valued at approximately $2,925,944.04. This trade represents a 4.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 511,413 shares of company stock valued at $283,666,212. 8.60% of the stock is owned by corporate insiders.

United Therapeutics Stock Down 0.6%

Shares of UTHR stock opened at $575.79 on Friday. United Therapeutics Corporation has a twelve month low of $272.12 and a twelve month high of $609.35. The stock’s fifty day simple moving average is $556.50 and its 200 day simple moving average is $506.65. The firm has a market capitalization of $24.44 billion, a P/E ratio of 21.25, a P/E/G ratio of 1.83 and a beta of 0.60.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. During the same quarter last year, the business earned $6.63 EPS. The firm’s quarterly revenue was down 1.6% compared to the same quarter last year. As a group, equities research analysts expect that United Therapeutics Corporation will post 27.64 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have weighed in on UTHR shares. Morgan Stanley set a $516.00 target price on United Therapeutics in a research note on Thursday, May 7th. Royal Bank Of Canada decreased their price target on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Oppenheimer boosted their price target on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a report on Thursday, February 26th. UBS Group upped their price objective on United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research report on Thursday, March 5th. Finally, Cantor Fitzgerald raised their price objective on United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research note on Thursday, March 12th. Eleven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $619.42.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.